MDCO: Medicines Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MDCO: Medicines Company

MDCO 84.90

0.0%

Jan 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rich1 who wrote (77)	5/10/2003 10:18:05 AM
From: Mike	Read Replies (2) of 125

Just wanted to post a little further information on MDCO. Would be great to get a real discussion going. Oh well for those who see or read the board please participate. Ok so were in almost mid May and almost 1/2 way thru the current qtr. What do we have going for MDCO? First the sales line is not known. If you look at the sequential sales last qtr vs the prior the sales growth was not hugely impressive. The key item here is going to be seqential sales growth. The last qtrs growth could be attributed to inventory growth at the wholesale level. Please look at the previous posts to look over this analysis. Now this increased wholesale inventory is not a red flag but has to be watched. Next item is the sales staff for MDCO is up to 97 reps. This is great to have as many people selling the product as possible. Hopefully all these new reps will start to really contribute for the 3rd qtr. Not saying they might not be contributing now but it take time to get up to speed. Next is the release of the Cypher stent. I really do think this is going to help Angiomax's cause. The savings data from Replace II will hold great weight in the decision and will play well. We will have to see with the release of the Cypher whether we see a nice increase in procedure volumes. The next big event is the publication of the 20 patient trial for the use of Angiomax in open heart procedures. This product and this procedure are a match made in investment heaven. Mark my words. This is going to be the biggest growth area for MDCO in late 2004. The results should be published on this small 20 patient trial in late summer. It will be interesting to to hear an update on the Acuity trial and the expanded trial for open heart. I hope the same data collection strategy is used as Replace II. The Replace II trial was a homerun for results and also how the company handled the entire trial. Lets hope the same for the other trials. Another item that we are waiting for is full approval on the Chemilog process. This will help margins and profitability going forward. One other thing that is very important are profit projections for 2004. Previous to the secondary offering profit projections for 2004 were for MDCO to be profitable and make $0.68/share. I will have to look to see if these projections have changed as a result of the secondary. I think this projection is realistic and obtainable. We will have to see what "forward pe" will be assigned to the stock. Good investing to all and jump on the MDCO bandwagon, Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next